P-Cresyl Sulfate Is a Valuable Predictor of Clinical Outcomes in Pre-ESRD Patients

الملخص EN

Background/Aims.

Previous studies have reported p-cresyl sulfate (PCS) was related to endothelial dysfunction and adverse clinical effect.

We investigate the adverse effects of PCS on clinical outcomes in a chronic kidney disease (CKD) cohort study.

Methods.

72 predialysis patients were enrolled from a single medical center.

Serum biochemistry data and PCS were measured.

The clinical outcomes including cardiovascular event, all-cause mortality, and dialysis event were recorded during a 3-year follow-up.

Results.

After adjusting other independent variables, multivariate Cox regression analysis showed age (HR: 1.12, P=0.01), cardiovascular disease history (HR: 6.28, P=0.02), and PCS (HR: 1.12, P=0.02) were independently associated with cardiovascular event; age (HR: 0.91, P<0.01), serum albumin (HR: 0.03, P<0.01), and PCS level (HR: 1.17, P<0.01) reached significant correlation with dialysis event.

Kaplan-Meier analysis revealed that patients with higher serum p-cresyl sulfate (>6 mg/L) were significantly associated with cardiovascular and dialysis event (log rank P=0.03, log rank P<0.01, resp.).

Conclusion.

Our study shows serum PCS could be a valuable marker in predicting cardiovascular event and renal function progression in CKD patients without dialysis.